Role of PTEN in TNFα induced insulin resistance
Creators
- 1. National Institute of Diabetes & Digestive & Kidney Disease, National Institutes of Health, Bethesda, MD 20892 (United States)
- 2. Wellcome Trust Medical Research Council Institute of Metabolic Science, Cambridge CB2 0QQ (United Kingdom)
- 3. Medicine and Research Services, Veterans Association Medical Center, Memphis, TN 38104 (United States)
- 4. Departments of Medicine and Pharmacology, University of Tennessee Health Science Center, Memphis, TN 38163 (United States)
Description
Aims/hypothesis: PTEN may play a reversible role in TNFα induced insulin resistance, which has been linked to obesity-associated insulin resistance (IR). Methods: Western blots for PTEN and p-Akt were performed on H-411E liver cells incubated with insulin, TNFα, and in selected experiments VO-OHpic vanadium complex in the presence and absence of PTEN siRNA. Total PTEN was compared to β-actin loading control and p-Akt was compared to total Akt. Results: Western blot and Real Time RT-PCR experiments showed increased PTEN after TNFα treatment (p = 0.04); slightly decreased PTEN after insulin treatment; and slightly increased PTEN after insulin + TNFα treatment. PTEN siRNA markedly inhibited the TNFα-induced increase in PTEN (p < 0.01) without significantly changing the p-Akt levels. The vanadium complex, exhibiting insulin-like effects, also significantly prevented the TNFα-induced increase in PTEN. Combining insulin and VO-OHpic was additive, providing both proof of concept and insight into mechanism. Discussion: The PTEN increase due to TNFα treatment was reversible by both PTEN siRNA knockdown and VO-OHpic treatment. Thus, PTEN is identified as a potential new therapeutic target for reducing IR in Type 2 DM. - Highlights: • TNFα treatment induced a significant increase in PTEN in H-411E liver cells. • PTEN siRNA knockdown prevented this effect. • VO-OHpic (vanadium complex) treatment, like insulin, decreased PTEN protein levels. • Thus, PTEN is identified as a potential therapeutic target in DM Type 2
Availability note (English)
Available from http://dx.doi.org/10.1016/j.bbrc.2015.04.063Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2015.04.063;
- PII
- S0006-291X(15)00753-6;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 461
- Journal Issue
- 3
- Journal Page Range
- p. 533-536
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47031663
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- ACTIN; ADDITIVES; BLOOD; CHROMOSOMES; COMPARATIVE EVALUATIONS; CONTROL; FASTING; GLUCOSE; HYPOTHESIS; INSULIN; LIVER CELLS; MEMBRANES; METABOLIC DISEASES; POLYMERASE CHAIN REACTION; POLYVINYLS; RECEPTORS; VANADIUM; VANADIUM COMPLEXES
- Descriptors DEC
- ALDEHYDES; ANIMAL CELLS; BIOLOGICAL MATERIALS; BODY FLUIDS; CARBOHYDRATES; COMPLEXES; DISEASES; ELEMENTS; EVALUATION; GENE AMPLIFICATION; HEXOSES; HORMONES; MATERIALS; MEMBRANE PROTEINS; METALS; MONOSACCHARIDES; ORGANIC COMPOUNDS; ORGANIC POLYMERS; PEPTIDE HORMONES; POLYMERS; PROTEINS; SACCHARIDES; SOMATIC CELLS; TRANSITION ELEMENT COMPLEXES; TRANSITION ELEMENTS
Optional Information
- Copyright
- Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.